Seminar on myltibcillary leprosy

Reading File

Finding Sources

Searching PubMed

"multibacillary leprosy" AND treatment

Reading File

Loading Image

I now have everything needed for a comprehensive seminar. Here is the full structured presentation:

Seminar on Multibacillary (MB) Leprosy

1. Introduction and Definition

Leprosy (Hansen's disease) is a chronic infectious disease caused by Mycobacterium leprae, an obligate intracellular pathogen. It primarily affects the peripheral nerves and skin, but can also involve the eyes, mucous membranes, muscles, bones, testes, and internal organs.

Multibacillary (MB) leprosy refers to forms of leprosy in which the bacterial load is high because the host's cell-mediated immunity (CMI) against M. leprae is weak or absent. For treatment purposes, MB leprosy is defined as:

Ridley-Jopling classification: Lepromatous leprosy (LL), borderline lepromatous (BL), and mid-borderline (BB) with BI ≥ 2+
WHO operational classification: ≥6 skin lesions, OR any positive skin-smear result (irrespective of lesion count)

The cardinal principle is simple: strong CMI = few organisms (paucibacillary); weak CMI = many organisms (multibacillary).

2. Etiology

Feature	Detail
Organism	Mycobacterium leprae (Hansen's bacillus)
Type	Obligate intracellular; acid-fast bacillus (AFB)
Target cell	Schwann cells of peripheral nerves
Doubling time	~12 days (very slow)
Culture	Cannot be grown on artificial media; grown in mouse footpad or nine-banded armadillos
Genome	Highly reduced (3.3 Mb); ~50% coding genes

M. leprae uses PGL-1 (phenolic glycolipid-1) and a laminin-binding protein to invade Schwann cells and bind to the basal lamina of peripheral nerve-axon units, causing demyelination.

3. Epidemiology

Global Burden

In 1985: 5.2 million cases worldwide; by 2019 the global burden fell to 202,185 new cases detected annually
The South-East Asia Region (SEAR) accounts for ~71% of the global leprosy burden
India and Indonesia together contribute 74.4% of global new cases
~73.4% of new cases globally are multibacillary (2019 data)
Nine-banded armadillos (southern USA, South America) are a known animal reservoir
Cases of new grade-2 disability: 10,813 (5.34% of new cases in 2019)

India

Peak prevalence: 57.6 per 10,000 (1981); fell to <1 per 10,000 by December 2005 (elimination achieved at national level)
Disease remains endemic in certain high-burden states

WHO Global Leprosy Strategy 2016-2020: Key Targets

Zero grade-2 disability in children with new leprosy
New cases with grade-2 disability <1 per million population
Zero countries with discriminatory legislation against leprosy patients

Source: Community Medicine (K. Park, 9789382219163)

4. Transmission

Route: Mainly via nasal droplets from untreated MB patients; traumatic skin inoculation is also possible
Incubation period: 2-7 years, sometimes up to 4 decades
Infectivity: Low - most new cases have had prolonged close contact with an infected person
Once treated, an MB patient becomes non-infectious within 3 weeks of starting rifampicin (or after ~90 days of dapsone monotherapy)
Attack rate among household contacts of lepromatous cases: 4.4-12% within 5 years

5. Immunopathology

The CMI response to M. leprae is the key determinant of disease type and severity:

Feature	Tuberculoid (TT/BT) - Paucibacillary	Lepromatous (LL/BL) - Multibacillary
CMI to M. leprae	Strong	Absent/weak
Th1 response	Present (IL-2, IFN-γ)	Absent
CD4+ T cells in lesions	Abundant	Sparse (few CD8+ cells dominate)
Bacterial load	Very low	Very high
Granuloma formation	Well-formed, epithelioid	Absent; foamy macrophages
Lepromin test	Strongly positive	Negative
Humoral antibody	Low	High (anti-PGL-1)
Nerve damage	Focal, asymmetric	Bilateral, symmetric, slow

In lepromatous leprosy, foamy macrophages (Virchow cells) are loaded with organisms (globi). The absence of Th1 cytokines allows unrestrained bacterial multiplication.

Source: Microbiology (Jawetz, 9781260464283); Dermatology (Habif, 9780323547536)

6. Classification

Ridley-Jopling Classification (Research/Detailed)

Type	Abbreviation	Bacterial Index	Lesions	CMI
Polar tuberculoid	TT	0	1-2, large, defined	+++
Borderline tuberculoid	BT	0-1+	<5, defined	++
Mid-borderline	BB	2-3+	Multiple, "punched-out"	+
Borderline lepromatous	BL	3-4+	Multiple, asymmetric	+/-
Polar lepromatous	LL	5-6+	Numerous, symmetric, diffuse	0

BB, BL, and LL = MULTIBACILLARY

Borderline disease is unstable and tends to "downgrade" (shift toward LL) over time without treatment.

WHO Operational Classification (Field Use)

Paucibacillary (PB): <6 skin lesions, smear negative
Multibacillary (MB): ≥6 skin lesions, OR any smear-positive result

7. Clinical Features of Multibacillary Leprosy

7a. Lepromatous Leprosy (LL) - The Prototype of MB Disease

Skin:

Multiple, small, poorly defined, hypopigmented or erythematous macules - numerous and symmetrically distributed
Minimal or no loss of sensation over early macular lesions
Progressive diffuse infiltration of skin - especially forehead, lips, and ears giving a "leonine facies" (lion-like appearance)
Madarosis: Loss of lateral third of eyebrows, then eyelashes, then body hair (scalp hair spared)
Lepromas: Nodules on ear lobes, brow, nose, chin, elbows, knees
Skin has a waxy, shiny "varnished" appearance
No change in sweating initially

Nerves:

Nerve involvement is bilateral and symmetric ("stocking-glove" distribution)
Develops slowly; can be mistaken for diabetic neuropathy
Peripheral neuropathy leading to deformity and non-healing plantar ulcers

Systemic involvement:

Nasal: obstruction, epistaxis, collapse of nasal septum ("saddle nose")
Eyes: lagophthalmos, corneal anesthesia, iritis, blindness
Testes: atrophy, gynecomastia, infertility
Reticuloendothelial system involvement
Loss of nasal bones, sometimes digits

Lepromatous leprosy - cutaneous plaques, infiltrates, loss of eyebrows

Lepromatous leprosy: cutaneous plaques, diffuse facial infiltration, and loss of eyebrows. (From Microbiology textbook, Jawetz)

7b. Histoid Leprosy (Variant of MB)

Uncommon form of MB Hansen disease
Large, yellow-red, shiny papules and nodules in dermis or subcutaneous tissue
Lesions on a background of normal skin (distinct from LL where background skin is abnormal)
Size 1-15 mm; favor buttocks, lower back, face, bony prominences
Can resemble molluscum contagiosum
Mostly described in patients with dapsone resistance or relapse after inadequate treatment
Very high bacillary load; BI often 6+

7c. Diffuse Leprosy of Lucio (DLL)

Striking variant seen mainly in western Mexico and parts of Latin America
Diffuse lepromatous infiltration without discrete lepromas
Complicated by Lucio phenomenon (erythema necroticans): ischemic vasculitic ulcers due to endothelial invasion

8. Nerve Involvement

The peripheral nerves most commonly enlarged/damaged in leprosy:

Nerve	Common Manifestation
Ulnar nerve (at elbow)	Claw hand (ring and little fingers)
Median nerve (at wrist)	Claw hand (index and middle fingers)
Common peroneal nerve (at knee)	Foot drop
Posterior tibial nerve (at ankle)	Plantar anesthesia, claw toes
Radial cutaneous nerve	Wrist drop
Facial nerve	Lagophthalmos
Greater auricular nerve	Visible/palpable enlarged nerve at neck
Supraorbital nerve	Anesthesia of forehead

In MB leprosy, nerve damage is bilateral, symmetric, and insidious. The feet develop midfoot disintegration, forefoot-hindfoot separation, and pressure ulcers.

Source: Internal Medicine (Firestein, 9780702081330)

9. Diagnosis

Clinical

≥6 hypopigmented/erythematous skin lesions with loss of sensation or altered sweating
Thickened, palpable peripheral nerves
Positive skin smear for AFB

Bacteriological

Slit-skin smear (ear lobes, nasal septum, affected skin edges): Stained with modified Ziehl-Neelsen (Fite-Faraco stain - weaker decolorizer than standard AFB, since M. leprae is more sensitive)
Bacterial Index (BI): Logarithmic scale 0-6+ (Ridley's log scale)
Morphological Index (MI): Percentage of solid-staining (viable) bacilli

Histopathology

Skin biopsy: In LL - foamy macrophages (Virchow cells) stuffed with bacilli; no formed granulomas; "Grenz zone" (clear zone between epidermis and infiltrate)
In TT/BT - well-formed epithelioid granulomas with giant cells and lymphocytes; few or no AFB

Serology

Anti-PGL-1 antibody (ELISA): Elevated in MB leprosy (correlates with bacillary load); useful for monitoring

Lepromin (Mitsuda) Test

Intradermal injection of killed M. leprae antigen
Positive (induration >5 mm at 3-4 weeks): TT and BT leprosy
Negative: LL leprosy
This test assesses CMI, NOT diagnosis of infection

PCR

Detects M. leprae DNA; useful in pure neural leprosy and smear-negative cases

10. Leprosy Reactions (Medical Emergencies)

Reactions are acute inflammatory episodes that can occur before, during, or after treatment and represent the leading cause of nerve damage.

Type 1 Reaction (Reversal Reaction)

Feature	Detail
Mechanism	Enhanced CMI response (Th1 upregulation) to M. leprae antigens
Occurs in	Borderline leprosy (BT, BB, BL) - most severe in BL
Timing	Usually after starting MDT
Skin	Existing lesions become swollen, erythematous, tender - can ulcerate
Nerves	Acute neuritis = Emergency - sudden loss of nerve function, permanent damage if untreated
Systemic symptoms	None (no fever, no chills)
Histology	Perivascular/perineural edema, lymphocytes; reduced bacilli
Treatment	Prednisolone 40-60 mg/day, taper over 3-6 months; DO NOT stop MDT

Type 2 Reaction (Erythema Nodosum Leprosum - ENL)

Feature	Detail
Mechanism	Immune complex-mediated vasculitis + elevated TNF-α
Occurs in	BL and LL leprosy (~50% of patients)
Timing	90% within first few years of MDT; also in pregnancy
Skin	Tender erythematous nodules (distinct new lesions, not pre-existing)
Systemic	Fever, malaise, myalgias, arthralgia, iritis, orchitis, lymphadenopathy, proteinuria
Nerves	Nerve damage via membrane attack complex generation
Treatment	Thalidomide (drug of choice, especially for chronic recurrent ENL); Prednisolone; clofazimine in high dose
Note	Thalidomide contraindicated in women of childbearing age (teratogenic)

Lucio Phenomenon (Type 3 Reaction)

Occurs only in Diffuse Leprosy of Lucio
Ischemic vasculitis - hemorrhagic ulcers
Systemic toxicity; potentially fatal

11. Deformities and Disabilities

WHO Disability Grading:

Grade	Hands/Feet	Eyes
0	No impairment	No impairment
1	Anesthesia, no visible deformity	Anesthesia; no visible impairment
2	Visible deformity (claw hand, foot drop, ulcer)	Severe visual impairment (VA <6/60)

Specific deformities in MB leprosy:

Clawing of fingers (ulnar, median nerve)
Wrist drop (radial nerve)
Foot drop (common peroneal nerve)
Plantar ulcers (posterior tibial nerve)
Lagophthalmos - corneal ulceration - blindness
Saddle nose (nasal bone/septal destruction)
Gynecomastia (testicular atrophy)
Absorption of phalanges (auto-amputation)

12. Treatment - WHO Multidrug Therapy (MDT)

MDT was introduced by WHO in 1981 to prevent drug resistance (particularly to dapsone monotherapy) and achieve cure.

WHO MDT Regimen for Multibacillary Leprosy (Adults)

Drug	Dose	Frequency
Rifampicin 600 mg	Supervised	Monthly
Clofazimine 300 mg	Supervised	Monthly
Clofazimine 50 mg	Self-administered	Daily
Dapsone 100 mg	Self-administered	Daily

Duration: 12 months (previously 24 months; reduced by WHO in 1998)

Pediatric Dosing (MB, age 10-14 years)

Rifampicin: 450 mg/month (supervised)
Clofazimine: 150 mg/month (supervised) + 50 mg alternate days
Dapsone: 50 mg/day

Mechanism of Action of Each Drug

Drug	Mechanism
Rifampicin	Inhibits DNA-dependent RNA polymerase; bactericidal; most potent anti-leprosy drug
Dapsone	Inhibits dihydropteroate synthase (like sulfonamides); bacteriostatic
Clofazimine	Binds DNA; generates ROS in macrophages; bactericidal + anti-inflammatory

Key Points on MDT

MDT renders patients non-infectious within 3 weeks (rifampicin effect)
Blister packs provided free of charge by WHO globally
Relapse rate after MB-MDT: very low (<1% over 9 years)
No documented clinically significant drug resistance to rifampicin with MDT regimens

Alternative/Second-Line Drugs (for drug intolerance/resistance)

Ofloxacin/Moxifloxacin (fluoroquinolones)
Minocycline (tetracycline)
ROM regimen (Rifampicin + Ofloxacin + Minocycline): single dose for single-lesion PB leprosy

Reactions During MDT

Continue MDT - never stop for reactions
Add prednisolone for Type 1 / ENL
Thalidomide for chronic ENL (adults, non-childbearing)
Increase clofazimine for chronic ENL (anti-inflammatory effect)

13. Prevention and Control

Measure	Details
MDT	Cornerstone of control; renders patient non-infectious rapidly
BCG vaccination	Provides 50-80% protection against leprosy (especially tuberculoid forms); recommended in endemic areas
Contact examination	All household contacts of MB cases should be examined annually for 5 years
Chemoprophylaxis	Single-dose rifampicin (SDR) for contacts reduces new cases by ~57% (Post-Exposure Prophylaxis for Leprosy - PEP)
Health education	Reduces stigma; promotes early case detection
Disability prevention	Self-care of anesthetic hands/feet; footwear; physiotherapy

14. Prognosis

MB leprosy is curable with complete MDT
Nerve damage present at diagnosis may partially recover but permanent disability can remain
Deformities that have developed do not reverse with MDT - surgical rehabilitation may be needed
Relapse after completing MDT is rare but possible (especially histoid leprosy)
Leprosy is NOT a death sentence - stigma is the greatest barrier to care-seeking

15. Summary

Feature	Multibacillary Leprosy
Types (R-J)	BB, BL, LL
WHO field criterion	≥6 lesions or smear positive
Key immunology	Absent CMI, Th2 dominance, foamy macrophages
Bacterial index	2+ to 6+
Lesions	Multiple, symmetric, poorly defined
Nerves	Bilateral, symmetric, slow damage
Lepromin	Negative
Reactions	Type 1 (reversal) in BL; Type 2 (ENL) in BL/LL
Treatment	Rifampicin + Clofazimine + Dapsone × 12 months
Global proportion	~73% of all new leprosy cases

Sources:

Dermatology - Habif's Clinical Dermatology (9780323547536)
Microbiology - Jawetz, Melnick & Adelberg (9781260464283)
Community Medicine - K. Park (9789382219163)
Internal Medicine - Firestein et al. (9780702081330)

Pharmacology seminar ??

Asking for Preferences

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive, multi-source pharmacology data. Here is the full seminar:

Pharmacology Seminar: Anti-Leprosy Drugs

1. Introduction

Leprosy is caused by Mycobacterium leprae, an obligate intracellular pathogen. Because M. leprae cannot be cultured on artificial media and has an extremely slow doubling time (~12 days), pharmacological management of leprosy required the development of specific long-course regimens. Dapsone monotherapy, introduced in the 1940s, led to widespread drug resistance by the 1970s, prompting WHO to introduce Multidrug Therapy (MDT) in 1981.

MDT combines three drugs: Rifampicin + Dapsone + Clofazimine. This combination:

Prevents emergence of resistance
Kills organisms at multiple targets
Renders the patient non-infectious within 3 weeks

"Only bactericidal drugs are used in multidrug regimens" - K. Park's Community Medicine

2. Classification of Anti-Leprosy Drugs

First-Line (WHO MDT Drugs)

Drug	Bactericidal/Static	Class
Rifampicin	Bactericidal (most potent)	Rifamycin
Clofazimine	Bactericidal + anti-inflammatory	Riminophenazine dye
Dapsone	Weakly bactericidal / bacteriostatic	Sulfone

Second-Line (for drug intolerance or resistance)

Drug	Class
Ofloxacin / Levofloxacin / Moxifloxacin	Fluoroquinolones
Minocycline	Tetracycline
Clarithromycin	Macrolide

Drugs for Reactions (not directly anti-mycobacterial)

Drug	Use
Prednisolone	Type 1 (reversal) reaction; also ENL
Thalidomide	Type 2 reaction (ENL) - drug of choice
Clofazimine (high dose)	Chronic recurrent ENL

3. Drug 1: Dapsone (DDS - Diaminodiphenyl Sulfone)

Dapsone molecular structure - two benzene rings connected via a sulfone group

Dapsone: symmetrical molecule with two benzene rings linked by -SO₂- and bearing an amino group on each ring (Katzung)

Chemistry

Diaminodiphenylsulfone (DDS)
Structurally related to sulfonamides
Available in 25 mg and 100 mg tablets

Mechanism of Action

Competitive inhibitor of dihydropteroate synthase (DHPS) in the folate synthesis pathway - the same enzyme inhibited by sulfonamides
Prevents synthesis of dihydrofolic acid, blocking bacterial DNA synthesis
Bacteriostatic against M. leprae at normal doses; weakly bactericidal at higher doses
Active metabolite dapsone hydroxylamine (DDS-NOH) contributes to anti-inflammatory effects (inhibits neutrophil chemotaxis, oxidative burst) - this is the basis of its use in non-infectious dermatoses

Pharmacokinetics

Parameter	Detail
Absorption	Well absorbed from GI tract; peak levels in 2-6 hours
Distribution	Widely distributed; high concentrations in skin (heavily infected skin has several times more drug)
Protein binding	~70-90%
Metabolism	Hepatic: N-acetylation (polymorphic - slow/fast acetylators, but clinically irrelevant for dosing) + N-hydroxylation by CYP2C19, 3A4, 2C9 → dapsone hydroxylamine (toxic metabolite)
Half-life	~28-30 hours (enterohepatic recirculation prolongs this)
Excretion	Bile (enterohepatic circulation); urine - mostly acetylated form
Note	Excreted in breast milk - risk of hemolysis in nursing infants

Dosage

Leprosy (adults): 100 mg/day orally (self-administered daily in MDT)
Pediatric: ~1-2 mg/kg/day (50 mg/day for ages 10-14)
Dose adjustment needed in renal failure
Starting dose: 50-100 mg/day to minimize hemolysis

Adverse Effects

1. Hematological (Most Important)

Effect	Mechanism	Notes
Hemolytic anemia	Dapsone hydroxylamine causes oxidant stress on RBCs, denaturing hemoglobin (Heinz body formation)	Most common side effect - ~20% of patients; dose-related; much worse in G6PD deficiency
Methemoglobinemia	Dapsone hydroxylamine oxidizes Hb-Fe²⁺ to Hb-Fe³⁺ (methemoglobin)	Usually subclinical; severe in NADH-methemoglobin reductase deficiency
Agranulocytosis	Idiosyncratic	Rare but life-threatening
Aplastic anemia	Idiosyncratic	Rare

Key point: G6PD screening should be done before starting dapsone. Dapsone hydroxylamine is the toxic metabolite responsible for hemolysis, methemoglobinemia, and hepatotoxicity. It is reduced back to dapsone by methemoglobin reductase and cytochrome b₅ reductase in erythrocytes.

2. Dapsone Hypersensitivity Syndrome (DDS Syndrome)

Rare but potentially fatal idiosyncratic reaction
Features: fever + exfoliative dermatitis/rash + hepatitis + lymphadenopathy + hemolysis (maculopapular rash + enlarged lymph glands)
Onset: usually 6-8 weeks after starting dapsone
Must be distinguished from leprosy reactions

3. Hepatic

Toxic hepatitis, cholestatic jaundice, transaminitis

4. Neurological

Peripheral neuropathy (rare)
Psychosis (rare)

5. Dermatological

Rash, pruritus, photosensitivity

6. Life-threatening adverse effects (summary)

Dapsone hypersensitivity syndrome
Hemolysis (can be severe in G6PD deficiency)
Methemoglobinemia
Agranulocytosis
Aplastic anemia
Hemophagocytic syndrome
TEN / Stevens-Johnson syndrome

Drug Interactions

Rifampicin (CYP450 inducer) reduces dapsone levels by ~50% - but still effective
Probenecid reduces renal excretion of dapsone - increases plasma levels
Trimethoprim increases dapsone levels (competition for metabolism)
Activated charcoal is useful in overdose (interrupts enterohepatic recirculation)

Contraindications

Severe G6PD deficiency (relative - use with caution)
Severe anemia (Hb <60% is a caution per Indian guidelines)
Dapsone hypersensitivity

Non-Leprosy Uses of Dapsone

Dapsone has broad utility as an anti-inflammatory drug in dermatology via DDS-NOH-mediated inhibition of neutrophil function:

As anti-infective:

PCP (Pneumocystis jirovecii pneumonia) - treatment + prophylaxis in HIV
Malaria (combination with pyrimethamine)
Leishmaniasis, nocardiosis

As anti-inflammatory (dermatology):

Dermatitis herpetiformis (highly responsive, hallmark indication)
Linear IgA dermatosis
Erythema elevatum diutinum
Bullous SLE, bullous pemphigoid
Pyoderma gangrenosum, Sweet syndrome
Subcorneal pustular dermatosis

Topical Dapsone (5% and 7.5% gel):

FDA-approved for acne vulgaris
No systemic hemolysis even in G6PD-deficient patients
Safe for topical use without G6PD pre-testing

Sources: Fitzpatrick's Dermatology; Katzung Pharmacology; Lippincott Pharmacology; Community Medicine (K. Park)

4. Drug 2: Rifampicin (Rifampin)

Chemistry

Semisynthetic derivative of rifamycin B (produced by Amycolatopsis rifamycinica)
Macrocyclic antibiotic; large complex structure

Mechanism of Action

Inhibits DNA-dependent RNA polymerase (DDRP) - specifically the β-subunit (encoded by rpoB gene)
Blocks initiation of RNA synthesis, NOT elongation
Bactericidal - most potent drug against M. leprae
A single dose of 1500 mg or 3-4 daily doses of 600 mg kills 99% of viable organisms
Effective even when given at monthly intervals - a major clinical advantage

Pharmacokinetics

Parameter	Detail
Absorption	Well absorbed orally; reduced by food
Distribution	Widely distributed; penetrates cells, CSF, abscesses
Metabolism	Hepatic; auto-induction of CYP450 enzymes (self-accelerating metabolism)
Half-life	~3.5 hours (but effective in monthly dosing due to concentration-dependent killing)
Excretion	Primarily bile/feces; some renal
Characteristic	Turns body fluids orange-red (urine, tears, sweat, saliva, sputum) - harmless but important to warn patients

Dosage in MDT

Adults: 600 mg once monthly, supervised (to ensure ingestion)
Children (10-14 yrs): 450 mg once monthly
Monthly dosing exploits rifampicin's bactericidal concentration-dependent killing of M. leprae

Adverse Effects

Hepatotoxicity - most serious; monitor LFTs
Flu-like syndrome (fever, chills, myalgias) - especially with intermittent dosing
Rash, urticaria
Thrombocytopenia, hemolytic anemia (intermittent high-dose)
Nephritis (rare)
Cholestasis
GI upset (nausea, vomiting, abdominal pain) - anorexia
Shock and collapse reported in rare cases (monitor for 1 hour post-dose)

Drug Interactions (Critical - Major Enzyme Inducer)

Rifampicin is a potent inducer of CYP450 enzymes (CYP3A4, CYP2C9, CYP2C19, P-glycoprotein):

Reduces levels of: oral contraceptives (risk of unintended pregnancy), warfarin, corticosteroids, antiretrovirals, antifungals, calcium channel blockers, anticonvulsants
Clinical implication: patients on rifampicin-containing MDT may need alternative contraception

Resistance

Resistance develops rapidly if used as monotherapy
rpoB gene mutations → rifampicin-resistant strains
MDT prevents resistance by combining with dapsone and clofazimine

5. Drug 3: Clofazimine

Chemistry

Fat-soluble riminophenazine dye - appears as red-orange/brick-red crystals
Originally synthesized in 1954 as a potential anti-TB drug; licensed for leprosy in 1969
Also has current roles in MDR-TB (WHO Group A drug) and NTM infections

Mechanism of Action (Multifactorial)

Membrane disruption - directly damages mycobacterial cell membrane
Inhibition of mycobacterial phospholipase A2
Inhibition of microbial K⁺ transport
Generation of hydrogen peroxide and cytotoxic ROS (redox cycling)
Interference with bacterial electron transport chain
Efflux pump inhibition
Anti-inflammatory effects: inhibits macrophages, T cells, neutrophils, and complement

The dual bactericidal + anti-inflammatory action is unique and makes it valuable for preventing/suppressing ENL reactions.

"ENL may not develop in patients treated with clofazimine" - Lippincott Pharmacology

Pharmacokinetics

Parameter	Detail
Absorption	Oral; bioavailability 45-60% (increased 2-fold by high-fat meals; decreased by antacids)
Distribution	Extremely lipophilic; huge volume of distribution (~10,000 L); accumulates in reticuloendothelial tissues, skin, intestinal mucosa, mesenteric lymph nodes, body fat; does NOT enter CNS
Metabolism	Hepatic: hydrolytic dehalogenation, deamination, glucuronidation, hydroxylation
Half-life	~35 days with sustained dosing (due to tissue accumulation and slow release) - this permits intermittent monthly dosing
Excretion	Primarily feces; drug crystals visible inside phagocytic cells at autopsy
Crystals	Crystalline deposits found in intestinal mucosa, liver, spleen, lymph nodes at autopsy

Dosage in MDT

Adults: 300 mg once monthly (supervised) + 50 mg daily (self-administered)
Children (10-14 yrs): 150 mg monthly + 50 mg on alternate days
For ENL: clofazimine 100-200 mg/day (anti-inflammatory dose)

Adverse Effects

Effect	Details
Skin discoloration	Most prominent; pink → reddish-brown → brownish-black (dose-dependent); also affects conjunctivae, urine, sputum, sweat. Fades in 6-12 months after stopping; traces may persist up to 4 years
Ichthyosis	Dry, scaly skin particularly on shins and forearms
GI effects	40-50% of patients; cramps, diarrhea, nausea, weight loss; due to crystal deposition in small bowel wall; rarely requires surgery
QT prolongation	ECG monitoring warranted, especially when combined with other QT-prolonging drugs
Psychosocial distress	Skin discoloration socially disabling in many patients; major cause of non-adherence (inadvertently "outs" patients as leprosy patients)

Important warning: Abdominal pain in a patient on clofazimine should raise suspicion of intestinal crystal deposition (enteritis/obstruction). Crystal deposition has been found in multiple organs at autopsy.

Drug Interactions

Anti-inflammatory effects of clofazimine may be inhibited by dapsone (potential pharmacodynamic antagonism)
Antacids reduce clofazimine absorption by ~30%

Resistance

Associated with mutations in Rv0678 (repressor of mmpS5-mmpL5 efflux pump) - cross-resistance with bedaquiline
Mutations in pepQ and Rv1979c also involved

6. WHO MDT Regimen Summary

Multibacillary Leprosy (Adults) - 12 months

Drug	Monthly (Supervised)	Daily (Self-administered)
Rifampicin	600 mg	-
Clofazimine	300 mg	50 mg
Dapsone	-	100 mg

Paucibacillary Leprosy (Adults) - 6 months

Drug	Monthly (Supervised)	Daily (Self-administered)
Rifampicin	600 mg	-
Dapsone	-	100 mg

(Clofazimine is NOT used in PB leprosy due to psychosocial concerns about skin discoloration for a relatively mild/limited disease)

Key Operational Features of MDT

Blister pack system - each pack contains all drugs for one month, provided free of charge by WHO
Supervised monthly administration ensures at least one dose is witnessed
Non-infectious within 3 weeks of starting (rifampicin effect)
Cure rate: ~99%
Relapse rate: <1% (except in patients with BI ≥4 at start, where relapse can reach 4-7 per 100 person-years)

7. Second-Line Anti-Leprosy Drugs

Used when patients are intolerant to first-line drugs or when drug resistance (especially rifampicin resistance) is confirmed.

Fluoroquinolones

Drug	Dose	Notes
Ofloxacin	400 mg/day	Most studied; inhibits DNA gyrase + topoisomerase IV
Levofloxacin	Standard dose	Active isomer of ofloxacin
Moxifloxacin	Standard dose	More potent; shorter course possible (ROM regimen)

ROM regimen (single-dose for single-lesion PB leprosy): Rifampicin 600 mg + Ofloxacin 400 mg + Minocycline 100 mg (single dose)

Minocycline

Tetracycline antibiotic
Inhibits 30S ribosomal subunit (protein synthesis inhibitor)
Bactericidal against M. leprae
Clearance of bacilli from skin was faster than dapsone or clofazimine, similar to ofloxacin
Dose: 100 mg/day
May shorten duration of MB-MDT if added to regimen

Clarithromycin

Macrolide; inhibits 50S ribosomal subunit
Active against M. leprae
Used in combination for rifampicin-resistant leprosy

For Rifampicin-Resistant Leprosy (WHO Guidelines)

Phase 1 (6 months): At least 2 second-line drugs (clarithromycin, minocycline, or a quinolone) + clofazimine daily

Phase 2 (18 months): Clofazimine + one second-line drug daily

For rifampicin AND ofloxacin dual resistance: Clarithromycin + minocycline + clofazimine for 6 months, then clarithromycin or minocycline + clofazimine for 18 months

Source: Harrison's Principles of Internal Medicine, 22nd Edition (2025)

8. Drugs for Leprosy Reactions

Thalidomide (for ENL - Type 2 Reaction)

Feature	Detail
History	Withdrawn in 1961 for severe teratogenicity (phocomelia); later found effective in ENL; FDA re-approved for ENL in 1998
Classification	Orphan drug (FDA)
Mechanism	Inhibits TNF-α production; immunomodulatory effects on T cells and cytokines (IL-12, IFN-γ); anti-angiogenic
Indication	Moderate-to-severe ENL (acute and maintenance); first-line drug for ENL
Dose	100-300 mg/day
Toxicities	Teratogenic (absolute contraindication in pregnancy - phocomelia, limb defects); peripheral neuropathy; sedation; constipation; DVT; thromboembolic events
Prescribing	Must be used under strict REMS program (STEPS program in USA); mandatory contraception for women of childbearing potential

Corticosteroids (for Type 1 Reversal Reaction and ENL)

Prednisolone 40-60 mg/day, tapered over 3-6 months
Mandatory for reversal reactions with neuritis (nerve function emergency)
Also used in ENL when thalidomide is contraindicated (e.g., women of childbearing age)
MDT must NEVER be stopped when treating reactions

Clofazimine (High Dose for Chronic ENL)

100-200 mg/day
Anti-inflammatory effect takes 4-6 weeks to manifest
Used as a steroid-sparing agent in chronic recurrent ENL

9. Rationale for Combination Therapy (MDT)

Principle	Explanation
Prevention of resistance	Each drug targets a different bacterial pathway; the probability of spontaneous resistance to all three simultaneously is negligible
Complementary killing	Rifampicin kills proliferating organisms; dapsone blocks folate; clofazimine attacks dormant/intracellular bacilli
Shortened duration	Triple therapy allows cure in 12 months vs. years with dapsone monotherapy
Preventing ENL	Clofazimine's anti-inflammatory component suppresses the immune complex reactions
Compliance	Blister packs, monthly supervision, and free provision enhance adherence

10. Drug Comparison Table

Feature	Rifampicin	Dapsone	Clofazimine
Class	Rifamycin	Sulfone	Riminophenazine dye
Bactericidal?	Yes (most potent)	Weakly bactericidal / bacteriostatic	Yes
Target	RNA polymerase (rpoB)	Dihydropteroate synthase (DHPS)	Membrane + electron transport + K⁺ transport + ROS
Anti-inflammatory?	No	No (but DDS-NOH inhibits neutrophils)	Yes (major feature)
Half-life	~3.5 h (short, but effective monthly)	~28-30 h	~35 days
Skin pigmentation	Turns fluids orange	None	Red-brown discoloration
Dosing in MDT	600 mg monthly (supervised)	100 mg daily	300 mg monthly + 50 mg daily
Key toxicity	Hepatotoxicity; CYP450 induction	Hemolysis; methemoglobinemia	Skin discoloration; GI toxicity; QT prolongation
G6PD concern	No	Yes (major)	No
CNS penetration	Yes	Yes	No
Use in ENL	No direct role	Dapsone itself can trigger ENL	Suppresses ENL (key benefit)

11. Special Populations

Population	Considerations
Pregnancy	MDT is safe; dapsone - no proven teratogenicity (Category C); thalidomide absolutely contraindicated; clofazimine - crosses placenta, neonatal discoloration possible
G6PD deficiency	Screen before dapsone; severe hemolysis risk; substitute dapsone with clofazimine if necessary
Renal failure	Reduce dapsone dose; rifampicin and clofazimine are primarily hepatically/biliary excreted - relatively safer
Children	Weight-based dosing; same 3-drug MDT for MB disease
HIV co-infection	MDT can be given; rifampicin interactions with antiretrovirals must be managed carefully

12. Monitoring During MDT

Drug	Monitoring Parameter
Dapsone	CBC (hemolysis), LFTs, G6PD screen pre-treatment
Rifampicin	LFTs, CBC, urine color warning
Clofazimine	Skin color counseling, GI symptoms, ECG (QT)
All drugs	Skin smear (BI) every 6 months, disability grading

13. Summary: Key Points for Exams

Most potent anti-leprosy drug: Rifampicin (bactericidal; kills 99% organisms with 3-4 doses)
Drug of choice for ENL: Thalidomide (FDA approved 1998 for ENL)
Most common adverse effect of dapsone: Hemolytic anemia (dose-related; worst in G6PD deficiency)
Toxic metabolite of dapsone: Dapsone hydroxylamine (DDS-NOH) - causes hemolysis + methemoglobinemia
Why clofazimine is given in MB leprosy but NOT PB: To prevent ENL reactions (its anti-inflammatory property)
Half-life of clofazimine: ~35 days (extremely long due to tissue accumulation)
ROM regimen: Single-dose Rifampicin + Ofloxacin + Minocycline for single-lesion PB leprosy
Rifampicin CYP interaction: Potent inducer - reduces OCP efficacy, warfarin, etc.
Dapsone syndrome: Fever + rash + lymphadenopathy + hepatitis; idiosyncratic; onset 6-8 weeks
Clofazimine + QT prolongation: Monitor ECG, especially with other QT-prolonging drugs
MDT duration: MB = 12 months; PB = 6 months
Type 1 reaction treatment: Prednisolone (nerve function emergency - do NOT stop MDT)

Sources:

Katzung's Basic & Clinical Pharmacology, 16th Ed. (9781260463309)
Goodman & Gilman's The Pharmacological Basis of Therapeutics (9781264258079)
Lippincott Illustrated Reviews: Pharmacology (9781975170561)
Fitzpatrick's Dermatology, 9th Ed. (9780071837781)
Harrison's Principles of Internal Medicine, 22nd Ed. (9781265977061)
K. Park's Community Medicine (9789382219163)

Seminar on multi bCillary pharmacology

Based on your previous two seminars, it looks like you want a combined seminar covering the pharmacology specific to multibacillary (MB) leprosy - essentially the MDT drugs (Rifampicin, Dapsone, Clofazimine) in the context of MB disease, reactions, second-line agents, and special situations.

I already have all the content from the textbooks loaded in our conversation. Here is the full integrated seminar:

Seminar: Pharmacology of Multibacillary Leprosy

1. Introduction

Multibacillary (MB) leprosy represents the high-bacterial-load end of the leprosy spectrum (BB, BL, LL types). Its pharmacological management is more complex than paucibacillary disease because:

The bacterial burden is enormous (Bacterial Index up to 6+)
Treatment duration is longer (12 months vs. 6 months)
The risk of leprosy reactions - particularly ENL (Type 2) - is high
Clofazimine is added specifically to combat reactions and the higher bacillary load
Relapse, though rare, is more likely in patients with very high initial BI (≥4)

The fundamental pharmacological strategy is WHO Multidrug Therapy (MDT), introduced in 1981 after widespread dapsone resistance emerged from decades of monotherapy.

2. Why Multidrug Therapy?

Problem with Monotherapy	MDT Solution
Dapsone resistance by 1970s	Three drugs with different targets - resistance to all three simultaneously is negligible
Long treatment duration (years)	Combination kills organisms faster; 12 months is sufficient
ENL reactions	Clofazimine's anti-inflammatory action suppresses ENL
High relapse rate	Triple bactericidal pressure sterilizes tissue faster

"The fall in prevalence rate is largely explained by improvement in management of cases, very low rates of relapse, high cure rates, absence of drug resistance and shorter duration of treatment with MDT." - K. Park's Community Medicine

3. The Three Pillars of MB-MDT

At a glance

Drug	Dose in MB-MDT	Frequency	Mode
Rifampicin	600 mg	Once monthly	Supervised
Clofazimine	300 mg	Once monthly	Supervised
Clofazimine	50 mg	Daily	Self-administered
Dapsone	100 mg	Daily	Self-administered

Duration: 12 months

Pediatric dosing (10-14 years): Rifampicin 450 mg monthly + Clofazimine 150 mg monthly + 50 mg on alternate days + Dapsone 50 mg daily.

4. Drug 1 - Rifampicin: The Backbone

Why it is the most important drug

Rifampicin is the only highly bactericidal drug against M. leprae. It kills 99% of viable organisms with just 3-4 consecutive daily doses of 600 mg. This is why:

It renders patients non-infectious within 3 weeks
It is given monthly under supervision (because even one monthly dose has enormous killing power)
It is the single most effective anti-leprosy drug ever discovered

Mechanism

Rifampicin binds the β-subunit of DNA-dependent RNA polymerase (DDRP), encoded by the rpoB gene, blocking initiation of RNA transcription. This halts protein synthesis and kills the organism.

Pharmacokinetics relevant to MB leprosy

Parameter	Clinical Relevance
Well absorbed orally	Standard oral route is effective
Half-life ~3.5 hours	Short, but concentration-dependent killing means monthly dosing is bactericidal
Potent CYP450 inducer	Reduces efficacy of oral contraceptives, warfarin, corticosteroids used for reactions
Turns body fluids orange	Warn patient - urine, tears, sweat turn orange; harmless
Penetrates cells and tissues	Reaches intracellular M. leprae in Schwann cells and macrophages

Key adverse effects in MB leprosy context

Effect	Clinical Note
Hepatotoxicity	Monitor LFTs; especially relevant since patients may also be on corticosteroids for reactions
Flu-like syndrome	With intermittent (monthly) dosing - fever, myalgias, rigors
GI upset	Anorexia, nausea, vomiting; monitor patient for 1 hour after supervised dose
Thrombocytopenia	Rare; with intermittent dosing
CYP450 induction	Reduces plasma levels of dapsone (~50%); reduces corticosteroid levels when used for reactions - may need higher steroid doses
Orange discoloration	Body fluids - not harmful but counsel patients

Resistance

rpoB mutations confer resistance
Rifampicin resistance in leprosy is rare but reported from several countries
MDT prevents resistance through combination therapy
If rifampicin-resistant: switch to second-line regimen (see Section 9)

5. Drug 2 - Dapsone: The Backbone Partner

Role in MB-MDT

Dapsone is given daily as the self-administered component of MDT. Though only weakly bactericidal, its daily continuous action complements rifampicin's monthly bactericidal pulses and prevents regrowth between doses.

Mechanism

Dapsone competitively inhibits dihydropteroate synthase (DHPS) - the same target as sulfonamides - blocking conversion of para-aminobenzoic acid (PABA) to dihydropteroic acid in the folate synthesis pathway. This prevents bacterial DNA synthesis.

Active metabolite (DDS-NOH / dapsone hydroxylamine):

Produced by CYP2C19, 3A4, 2C9 in liver
Toxic - causes hemolysis and methemoglobinemia
Also has anti-inflammatory activity (inhibits neutrophil chemotaxis) - relevant in leprosy reactions

Pharmacokinetics relevant to MB leprosy

Parameter	Clinical Relevance
Well absorbed orally	Reliable daily self-administration
Half-life ~28-30 hours	Enterohepatic recirculation prolongs action; once-daily dosing is effective
High skin concentration	Skin infected with M. leprae contains several times more drug than normal skin
Hepatic N-acetylation	Polymorphic (slow/fast acetylators) - but clinically irrelevant; do not need to check
Excreted in breast milk	Risk of hemolysis in nursing infants
Renal excretion	Dose reduction needed in renal failure

Adverse effects specific to MB leprosy

Effect	Mechanism	Clinical Relevance
Hemolytic anemia	DDS-NOH → oxidant stress on RBCs → Heinz body formation	~20% of patients; dose-related; much worse in G6PD deficiency - test before starting
Methemoglobinemia	DDS-NOH oxidizes Fe²⁺ → Fe³⁺ (methemoglobin)	Usually subclinical; severe in NADH-methemoglobin reductase deficiency
ENL triggering	Dapsone therapy itself can precipitate ENL reactions in lepromatous patients	Can be difficult to distinguish from disease progression - important clinical trap
Dapsone syndrome	Idiosyncratic; fever + rash + hepatitis + lymphadenopathy	Onset 6-8 weeks; rare but potentially fatal
Agranulocytosis	Idiosyncratic	Rare; stop drug immediately
Peripheral neuropathy	Direct toxicity	Rare

Critical Point: G6PD screening before starting dapsone - G6PD-deficient patients develop severe hemolysis. If G6PD deficient, dapsone can be replaced by clofazimine (additional dose) in the MDT regimen.

Critical Point: Hemoglobin should be ≥60% (not severely anemic) before starting dapsone (Indian national guidelines). Prescribe iron supplements routinely.

Dapsone and ENL (Type 2 Reaction)

In MB leprosy patients on dapsone-containing MDT, ENL can develop as an immune complex-mediated reaction. This is not a drug allergy - it is the immunological response to dying M. leprae antigens. Continue MDT; manage the reaction separately with thalidomide or corticosteroids.

6. Drug 3 - Clofazimine: The Multi-Role Drug

Clofazimine is uniquely valuable in MB leprosy because it serves two distinct pharmacological roles simultaneously: anti-mycobacterial AND anti-inflammatory.

Mechanism of action (multifactorial)

Membrane disruption - directly damages mycobacterial cell membrane integrity
Inhibition of mycobacterial phospholipase A2
Inhibition of K⁺ transport across bacterial membrane
Generation of ROS (H₂O₂ and superoxide) via redox cycling - directly toxic to bacteria
Disruption of electron transport chain
Efflux pump inhibition
Anti-inflammatory: inhibits macrophages, T lymphocytes, neutrophils, and complement activation

"ENL may not develop in patients treated with clofazimine" - Lippincott Pharmacology

Why clofazimine is essential in MB (but not PB) leprosy

Reason	Explanation
Higher bacterial load	More drug needed for sterilization
ENL prevention	MB patients (BL/LL) have ~50% risk of ENL; clofazimine's anti-inflammatory action prevents/suppresses it
Anti-inflammatory synergy	Reduces need for corticosteroids and thalidomide
Psychosocial (skin discoloration)	In PB leprosy (limited disease), adding clofazimine just for its anti-inflammatory benefit is not justified given the social stigma of discoloration

Pharmacokinetics relevant to MB leprosy

Parameter	Clinical Relevance
Oral bioavailability 45-60%	Increased 2-fold by high-fat meals - advise patients to take with food; antacids reduce absorption by 30%
Volume of distribution ~10,000 L	Massive tissue accumulation - drug reaches deep tissue M. leprae reservoirs
Half-life ~35 days	Extremely long; permits monthly supervised dosing + daily low-dose self-administration; residual drug persists months after stopping
Does NOT enter CNS	No CNS effects; not useful for neural leprosy in the brain
Crystal deposits in tissues	Intestinal mucosa, liver, spleen, lymph nodes - can cause obstructive GI complications
Metabolized in liver	4-step process: dehalogenation, deamination, glucuronidation, hydroxylation

Adverse effects specific to MB leprosy

Effect	Details
Skin discoloration	Most prominent and most distressing; dose-dependent; pink → reddish-brown → brownish-black; affects skin + conjunctivae + urine + sputum + sweat; fades in 6-12 months after stopping; traces may persist up to 4 years. This discoloration "outs" patients as leprosy patients, causing major psychosocial harm and treatment non-adherence. Must counsel extensively before starting.
Ichthyosis	Dry, scaling skin on shins and forearms
GI toxicity (40-50%)	Cramps, diarrhea, nausea, weight loss - due to crystal deposition in intestinal wall; rarely requires surgery
QT prolongation	ECG monitoring warranted, especially with other QT-prolonging agents
Accumulation in lesions	Clofazimine accumulates in active leprosy skin lesions, making them temporarily more prominent - warn patients

Drug interaction specific to MB leprosy

Dapsone inhibits the anti-inflammatory effects of clofazimine (pharmacodynamic antagonism) - Goodman & Gilman
Antacids reduce clofazimine absorption

7. The Pharmacological Basis of ENL Suppression by Clofazimine

ENL (Erythema Nodosum Leprosum / Type 2 reaction) is an immune complex-mediated vasculitis occurring in 50% of BL/LL patients. The reaction involves:

TNF-α overproduction
Elevated IL-1, IL-6
Complement activation with membrane attack complex (MAC) generation in nerves
Increased CD4:CD8 ratio in skin and blood

Clofazimine addresses this through:

Inhibition of macrophage and T-cell activation
Complement inhibition
Reduction of pro-inflammatory cytokines

However, the anti-inflammatory effect takes 4-6 weeks to develop - so acute ENL still requires immediate treatment with thalidomide or corticosteroids.

8. Treatment of Reactions in MB Leprosy

Golden Rule: NEVER stop MDT during a reaction

Stopping MDT allows bacterial regrowth. Reactions are immunological events - not drug toxicity. Continue MDT and treat the reaction separately.

Type 1 Reaction (Reversal Reaction) - Occurs in BL

Feature	Management
Mechanism	Upregulation of CMI (Th1 response) to M. leprae antigens
Emergency signal	Acute neuritis - sudden nerve function loss
Treatment	Prednisolone 40-60 mg/day, taper over 3-6 months
Rationale	Corticosteroids suppress the acute CMI inflammation within infected nerves
DO NOT use	Thalidomide (not effective for Type 1)

Type 2 Reaction (ENL) - Occurs in BL/LL

Scenario	Drug of Choice	Notes
Acute moderate-to-severe ENL	Thalidomide 100-300 mg/day	FDA-approved 1998 for ENL; inhibits TNF-α; most effective
Women of childbearing age	Prednisolone	Thalidomide absolutely contraindicated in pregnancy - phocomelia
Chronic recurrent ENL	Clofazimine 100-200 mg/day	Steroid-sparing; takes 4-6 weeks to work
Mild ENL	NSAIDs / Aspirin	Symptomatic relief only

Thalidomide in ENL - Pharmacology

Feature	Detail
Mechanism	Inhibits TNF-α synthesis; immunomodulation of IL-12, IFN-γ; anti-angiogenic
History	Withdrawn 1961 (phocomelia/limb defects in fetuses); re-approved FDA 1998 for ENL
Classification	Orphan drug (FDA)
Indication	Moderate-to-severe acute ENL; maintenance to prevent recurrence
Key toxicity	Absolute teratogen (phocomelia); peripheral neuropathy; sedation; DVT; thromboembolic events
Prescribing restriction	REMS/STEPS program in USA; mandatory contraception for women of childbearing potential

9. Second-Line Drugs for Resistant/Intolerant MB Leprosy

Used when: (a) patients cannot tolerate first-line drugs, or (b) rifampicin resistance is confirmed.

Individual Drug Substitutions (Intolerance)

Intolerant to	Substitute with
Rifampicin	Ofloxacin 400 mg/day OR Minocycline 100 mg/day
Dapsone	Clofazimine 50 mg/day (additional dose)
Clofazimine	Minocycline 100 mg/day OR Ofloxacin 400 mg/day

Rifampicin-Resistant Leprosy (WHO Protocol)

Phase 1 (6 months): Clofazimine + at least 2 of: clarithromycin, minocycline, ofloxacin/levofloxacin/moxifloxacin - all daily

Phase 2 (18 months): Clofazimine + one second-line drug daily

Rifampicin + Ofloxacin dual resistance: Clarithromycin + minocycline + clofazimine × 6 months → clarithromycin or minocycline + clofazimine × 18 months

Second-Line Drugs - Key Pharmacology

Drug	Class	Mechanism	Activity against M. leprae
Ofloxacin	Fluoroquinolone	Inhibits DNA gyrase + topoisomerase IV	Bactericidal; clearance similar to rifampicin
Minocycline	Tetracycline	Inhibits 30S ribosomal subunit	Bactericidal; clears bacilli faster than dapsone or clofazimine
Clarithromycin	Macrolide	Inhibits 50S ribosomal subunit	Bactericidal
Moxifloxacin	Fluoroquinolone	DNA gyrase + topo IV	Most potent fluoroquinolone; ROM regimen use

ROM regimen (single-lesion PB leprosy - not MB): Single dose of Rifampicin + Ofloxacin + Minocycline

10. Relapse in MB Leprosy - Pharmacological Approach

Cure rate with MDT: ~99%
Relapse defined as: increase in BI of ≥2+ over previous value at any single site, with clinical deterioration
Relapse rate: <1% overall; up to 4-7 per 100 person-years in patients with initial BI ≥4
Most relapses occur within 5 years of completing MDT

Treatment of relapse:

Re-treat with the same MB-MDT regimen (no dose escalation needed)
Resistance to all three MDT drugs simultaneously is extremely rare
Patients with MB disease require monitoring for at least 5 years after completing MDT

Source: Harrison's Principles of Internal Medicine, 22nd Edition (2025)

11. Drug Interactions Matrix for MB-MDT

Drug Pair	Interaction	Clinical Action
Rifampicin + Dapsone	Rifampicin reduces dapsone levels ~50% (CYP induction)	MDT doses are pre-adjusted for this
Rifampicin + Corticosteroids (for reactions)	Rifampicin reduces prednisolone levels	Use higher steroid doses (1.5-2x)
Rifampicin + Oral contraceptives	Rifampicin reduces OCP efficacy	Use alternative/barrier contraception
Clofazimine + Dapsone	Dapsone inhibits clofazimine's anti-inflammatory action	Unavoidable in MDT; clinically managed
Clofazimine + QT-prolonging drugs	Additive QT prolongation	Monitor ECG; avoid other QT drugs
Clofazimine + Antacids	Antacids reduce clofazimine absorption by ~30%	Separate dosing times

12. Special Situations in MB Leprosy Pharmacology

Situation	Pharmacological Consideration
G6PD deficiency	Screen before dapsone; if deficient, substitute dapsone with extra clofazimine; risk of life-threatening hemolysis
Pregnancy	MDT is safe; thalidomide absolutely contraindicated; clofazimine crosses placenta (neonatal skin discoloration); rifampicin + corticosteroids for reactions
HIV co-infection	MDT can be given; major rifampicin-antiretroviral interactions (especially PIs and NNRTIs); consider rifabutin substitution
Renal failure	Reduce dapsone dose; rifampicin and clofazimine are primarily biliary/hepatic - safer
Hepatic failure	Use all three drugs with caution; rifampicin most hepatotoxic; monitor LFTs
Children	Weight-adjusted dosing (see Section 3); same three-drug MDT
Histoid leprosy	MB regimen; often associated with prior dapsone resistance - confirm susceptibility

13. Monitoring During MB-MDT

Parameter	Frequency	Why
CBC (Hb, reticulocytes)	Monthly initially	Dapsone-induced hemolysis
LFTs	Monthly first 3 months, then 3-monthly	Rifampicin hepatotoxicity
G6PD level	Once before starting	Predicts dapsone hemolysis risk
Skin smear (BI, MI)	6-monthly	Assess bacteriological response
Disability grade assessment	At diagnosis, 6, 12 months	Monitor nerve function; detect reactions early
ECG	If high-risk or co-medications	Clofazimine QT prolongation
Skin counseling	Each visit	Clofazimine discoloration adherence

14. Exam High-Yield Summary

Question	Answer
Most potent anti-leprosy drug	Rifampicin
Only bactericidal drug in MB-MDT	Rifampicin (most potent); clofazimine also bactericidal
Drug that prevents ENL	Clofazimine
Drug of choice for ENL	Thalidomide
Why thalidomide cannot be used in pregnant women	Phocomelia (absolute teratogen)
Toxic metabolite of dapsone	Dapsone hydroxylamine (DDS-NOH)
Dapsone mechanism	Inhibits dihydropteroate synthase (DHPS)
Why rifampicin is given monthly (not daily) in MDT	Monthly supervised dose has enough bactericidal power; ensures compliance; even monthly dosing kills 99% viable organisms
Half-life of clofazimine	~35 days
Why clofazimine is not given in PB leprosy	Psychosocial harm of skin discoloration; ENL risk is low in PB disease
What makes clofazimine unique	Dual action: bactericidal + anti-inflammatory
Duration of MB-MDT	12 months
What to do during a leprosy reaction	Continue MDT; treat reaction separately
Dapsone hypersensitivity syndrome features	Fever + rash + hepatitis + lymphadenopathy (onset 6-8 weeks)
Clofazimine in pregnancy	Crosses placenta; neonatal skin discoloration; continue if necessary
Rifampicin color change	Turns body fluids orange-red (urine, tears, sweat)

Sources:

Katzung's Basic & Clinical Pharmacology, 16th Ed. (9781260463309)
Goodman & Gilman's Pharmacological Basis of Therapeutics (9781264258079)
Lippincott Illustrated Reviews: Pharmacology (9781975170561)
Fitzpatrick's Dermatology (9780071837781)
Harrison's Principles of Internal Medicine, 22nd Ed. (9781265977061)
K. Park's Textbook of Community Medicine (9789382219163)

This is a shared conversation. Sign in to Orris to start your own chat.